{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:21:40Z","timestamp":1787494900519,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T00:00:00Z","timestamp":1464048000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11011-016-9840-z","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T07:34:22Z","timestamp":1464075262000},"page":"1023-1029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice"],"prefix":"10.1007","volume":"31","author":[{"given":"Magdalena","family":"Dudek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Kuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ko\u0142aczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Olczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"\u017bmudzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Bednarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Pytka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Sapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kie\u0107-Kononowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,24]]},"reference":[{"key":"9840_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/oby.2006.6","volume":"14","author":"VL Albaugh","year":"2006","unstructured":"Albaugh VL, Henry CR, Bello NT, et al. (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14:36\u201351. doi: 10.1038\/oby.2006.6","journal-title":"Obesity (Silver Spring)"},{"key":"9840_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022662","volume":"6","author":"VL Albaugh","year":"2011","unstructured":"Albaugh VL, Singareddy R, Mauger D, Lynch CJ (2011) A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One 6:e22662. doi: 10.1371\/journal.pone.0022662","journal-title":"PLoS One"},{"key":"9840_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00011-004-1286-9","volume":"53","author":"RA Bakker","year":"2004","unstructured":"Bakker RA (2004) Histamine H3-receptor isoforms. Inflamm Res 53:509\u2013516. doi: 10.1007\/s00011-004-1286-9","journal-title":"Inflamm Res"},{"key":"9840_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bbr.2012.12.063","volume":"243","author":"C Brabant","year":"2013","unstructured":"Brabant C, Charlier Y, Tirelli E (2013) The histamine H3-receptor inverse agonist pitolisant improves fear memory in mice. Behav Brain Res 243:199\u2013204. doi: 10.1016\/j.bbr.2012.12.063","journal-title":"Behav Brain Res"},{"key":"9840_CR5","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, et al. (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 12:1068\u20131075. doi: 10.1016\/S1474-4422(13)70225-4","journal-title":"Lancet Neurol"},{"key":"9840_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","volume":"34","author":"C Deng","year":"2010","unstructured":"Deng C, Weston-Green K, Huang X-F (2010) The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuro-Psychopharmacol Biol Psychiatry 34:1\u20134. doi: 10.1016\/j.pnpbp.2009.11.009","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"9840_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141327","volume":"10","author":"M Dudek","year":"2015","unstructured":"Dudek M, Knutelska J, Bednarski M, et al. (2015a) A comparison of the anorectic effect and safety of the Alpha2-adrenoceptor ligands Guanfacine and Yohimbine in rats with diet-induced obesity. PLoS One 10:e0141327. doi: 10.1371\/journal.pone.0141327","journal-title":"PLoS One"},{"key":"9840_CR8","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s11011-015-9736-3","volume":"30","author":"M Dudek","year":"2015","unstructured":"Dudek M, Marcinkowska M, Bucki A, et al. (2015b) Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metab Brain Dis 30:1487\u20131494. doi: 10.1007\/s11011-015-9736-3","journal-title":"Metab Brain Dis"},{"key":"9840_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejphar.2016.02.047","volume":"776","author":"M Dudek","year":"2016","unstructured":"Dudek M, Knutelska J, Bednarski M, et al. (2016) Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. Eur J Pharmacol 776:146\u2013155. doi: 10.1016\/j.ejphar.2016.02.047","journal-title":"Eur J Pharmacol"},{"key":"9840_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","volume":"88","author":"HL Haas","year":"2008","unstructured":"Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183\u20131241. doi: 10.1152\/physrev.00043.2007","journal-title":"Physiol Rev"},{"key":"9840_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1517\/13543784.14.3.223","volume":"14","author":"AA Hancock","year":"2005","unstructured":"Hancock AA, Brune ME (2005) Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists\/inverse agonists. Expert Opin Investig Drugs 14:223\u2013241. doi: 10.1517\/13543784.14.3.223","journal-title":"Expert Opin Investig Drugs"},{"key":"9840_CR12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.lfs.2003.06.003","volume":"73","author":"AA Hancock","year":"2003","unstructured":"Hancock AA, Esbenshade TA, Krueger KM, Yao BB (2003) Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 73:3043\u20133072","journal-title":"Life Sci"},{"issue":"Suppl 1","key":"9840_CR13","first-page":"18","volume":"69","author":"JM Kane","year":"2008","unstructured":"Kane JM, Sharif ZA (2008) Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry 69(Suppl 1):18\u201331","journal-title":"J Clin Psychiatry"},{"key":"9840_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1124\/jpet.102.046987","volume":"305","author":"S Kapur","year":"2003","unstructured":"Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625\u2013631. doi: 10.1124\/jpet.102.046987","journal-title":"J Pharmacol Exp Ther"},{"key":"9840_CR15","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1007\/s00213-014-3540-3","volume":"231","author":"H Kim","year":"2014","unstructured":"Kim H, Park M, Lee S-K, et al. (2014) Phosphorylation of hypothalamic AMPK on serine(485\/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine. Psychopharmacology 231:4059\u20134069. doi: 10.1007\/s00213-014-3540-3","journal-title":"Psychopharmacology"},{"key":"9840_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/schbul\/sbs196","volume":"40","author":"CM Klingerman","year":"2014","unstructured":"Klingerman CM, Stipanovic ME, Bader M, Lynch CJ (2014) Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL\/6\u00a0J mice. Schizophr Bull 40:327\u2013340. doi: 10.1093\/schbul\/sbs196","journal-title":"Schizophr Bull"},{"key":"9840_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1517\/13543776.2010.509346","volume":"20","author":"D \u0141azewska","year":"2010","unstructured":"\u0141azewska D, Kie\u0107-Kononowicz K (2010) Recent advances in histamine H3 receptor antagonists\/inverse agonists. Expert Opin Ther Pat 20:1147\u20131169. doi: 10.1517\/13543776.2010.509346","journal-title":"Expert Opin Ther Pat"},{"key":"9840_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1517\/13543776.2014.848197","volume":"24","author":"D \u0141a\u017cewska","year":"2014","unstructured":"\u0141a\u017cewska D, Kie\u0107-Kononowicz K (2014) New developments around histamine H(3) receptor antagonists\/inverse agonists: a patent review (2010 - present). Expert Opin Ther Pat 24:89\u2013111. doi: 10.1517\/13543776.2014.848197","journal-title":"Expert Opin Ther Pat"},{"key":"9840_CR19","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/oby.2010.17","volume":"18","author":"M Liebig","year":"2010","unstructured":"Liebig M, Gossel M, Pratt J, et al. (2010) Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring) 18:1952\u20131958. doi: 10.1038\/oby.2010.17","journal-title":"Obesity (Silver Spring)"},{"key":"9840_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1124\/jpet.106.111039","volume":"320","author":"X Ligneau","year":"2007","unstructured":"Ligneau X, Perrin D, Landais L, et al. (2007) BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 320:365\u2013375. doi: 10.1124\/jpet.106.111039","journal-title":"J Pharmacol Exp Ther"},{"key":"9840_CR21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1124\/mol.55.6.1101","volume":"55","author":"TW Lovenberg","year":"1999","unstructured":"Lovenberg TW, Roland BL, Wilson SJ, et al. (1999) Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 55:1101\u20131107","journal-title":"Mol Pharmacol"},{"key":"9840_CR22","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/oby.2006.252","volume":"14","author":"K Malml\u00f6f","year":"2006","unstructured":"Malml\u00f6f K, Golozoubova V, Peschke B, et al. (2006) Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides. Obesity (Silver Spring) 14:2154\u20132162. doi: 10.1038\/oby.2006.252","journal-title":"Obesity (Silver Spring)"},{"key":"9840_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/PCC.v06n0101","volume":"6","author":"DD Miller","year":"2004","unstructured":"Miller DD (2004) Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 6:3\u20137","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"9840_CR24","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00228-014-1762-2","volume":"70","author":"B Misiak","year":"2014","unstructured":"Misiak B, Frydecka D, \u0141aczma\u0144ski \u0141, et al. (2014) Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. Eur J Clin Pharmacol 70:1433\u20131441. doi: 10.1007\/s00228-014-1762-2","journal-title":"Eur J Clin Pharmacol"},{"key":"9840_CR25","first-page":"180","volume":"7","author":"M Podogrodzka","year":"2010","unstructured":"Podogrodzka M, Jarema M (2010) Practical aspects of the use of olanzapine in the treatment of schizophrenia and bipolar disorders. Psychiatria 7:180\u2013188","journal-title":"Psychiatria"},{"key":"9840_CR26","first-page":"327","volume":"229","author":"RD Porsolt","year":"1977","unstructured":"Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn th\u00e9rapie 229:327\u2013336","journal-title":"Arch Int Pharmacodyn th\u00e9rapie"},{"key":"9840_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142499","volume":"10","author":"K Pytka","year":"2015","unstructured":"Pytka K, Partyka A, Jastrz\u0119bska-Wi\u0119sek M, et al. (2015a) Antidepressant- and anxiolytic-like effects of new dual 5-HT1 a and 5-HT7 antagonists in animal models. PLoS One 10:e0142499. doi: 10.1371\/journal.pone.0142499","journal-title":"PLoS One"},{"key":"9840_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pharep.2014.08.016","volume":"67","author":"K Pytka","year":"2015","unstructured":"Pytka K, Rapacz A, Zygmunt M, et al. (2015b) Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: the involvement of serotonergic system. Pharmacol Rep 67:160\u2013165. doi: 10.1016\/j.pharep.2014.08.016","journal-title":"Pharmacol Rep"},{"key":"9840_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ejphar.2015.07.041","volume":"764","author":"K Pytka","year":"2015","unstructured":"Pytka K, Walczak M, Kij A, et al. (2015c) The antidepressant-like activity of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one involves serotonergic 5-HT(1\u00a0a) and 5-HT(2\u00a0a\/C) receptors activation. Eur J Pharmacol 764:537\u2013546. doi: 10.1016\/j.ejphar.2015.07.041","journal-title":"Eur J Pharmacol"},{"key":"9840_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2016.04.005","author":"K Pytka","year":"2016","unstructured":"Pytka K, Kazek G, Siwek A, et al. (2016) HBK-7 \u2014 a new xanthone derivative and a 5-HT1A receptor antagonist with antidepressant-like properties. Pharmacol Biochem Behav. doi: 10.1016\/j.pbb.2016.04.005","journal-title":"Pharmacol Biochem Behav"},{"key":"9840_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","volume":"125","author":"GP Reynolds","year":"2010","unstructured":"Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment\u2013pharmacological mechanisms. Pharmacol Ther 125:169\u2013179. doi: 10.1016\/j.pharmthera.2009.10.010","journal-title":"Pharmacol Ther"},{"key":"9840_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29\u201339","journal-title":"Life Sci"},{"key":"9840_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","volume":"163","author":"J-C Schwartz","year":"2011","unstructured":"Schwartz J-C (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163:713\u2013721. doi: 10.1111\/j.1476-5381.2011.01286.x","journal-title":"Br J Pharmacol"},{"key":"9840_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/bph.12149","volume":"169","author":"M Uguen","year":"2013","unstructured":"Uguen M, Perrin D, Belliard S, et al. (2013) Preclinical evaluation of the abuse potential of pitolisant, a histamine H3 receptor inverse agonist\/antagonist compared with modafinil. Br J Pharmacol 169:632\u2013644. doi: 10.1111\/bph.12149","journal-title":"Br J Pharmacol"},{"key":"9840_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejphar.2007.11.078","volume":"585","author":"EM Zwaal Van der","year":"2008","unstructured":"Van der Zwaal EM, Luijendijk MCM, Adan RAH, la Fleur SE (2008) Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 585:130\u2013136. doi: 10.1016\/j.ejphar.2007.11.078","journal-title":"Eur J Pharmacol"},{"key":"9840_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","volume":"217","author":"K Weston-Green","year":"2011","unstructured":"Weston-Green K, Huang X-F, Deng C (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217:337\u2013346. doi: 10.1016\/j.bbr.2010.10.039","journal-title":"Behav Brain Res"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-016-9840-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-016-9840-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-016-9840-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-016-9840-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T14:55:47Z","timestamp":1567954547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-016-9840-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,24]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["9840"],"URL":"https:\/\/doi.org\/10.1007\/s11011-016-9840-z","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,24]]}}}